Skip to content

Search

Search managers or tickers

Baupost Group

Q1 2017 13F · by Seth Klarman, portfolio manager

As of
Mar 31, 2017
Filed
May 25, 2017
US stock
$8.4B · prev $7.6B
Positions
41 · prev 42
Options notional
$0
Documents
1· 1 amendment

Picture99.3% US stock

Full picture · of what this 13F reports is US stock

  • US stock listed on a US exchange 99.3%
  • Foreign stock not listed in the US 0.0%
  • Notes debt, at principal 0.7%
  • Puts at notional value 0.0%
  • Calls at notional value 0.0%

Moves20 since the prior filing

The book

Concentrated · behaves like 17 equal-sized positions

  1. Very concentrated
  2. Concentrated
  3. Focused
  4. Diversified

Moderate turnover · 57% a year, about 1.8 years per position

  1. Low
  2. Moderate
  3. High

Top 5 positions44% of US stock

  1. LNG Cheniere Energy Inc held held12.2%
  2. VSAT Viasat Inc held held10.0%
  3. unresolved Twenty First Centy Fox Inc held held7.3%
  4. unresolved Colony Northstar Inc new+7.33 pp new+7.337.3%
  5. SYF Synchrony Financial trimmed−2.69 pp trimmed−2.697.2%

Revealed late, restated

restated 0 rows corrected by the filer · US stock 0.00%; later quarters recomputed 13F-HR/A · May 25, 2017 ↗

Positions41 in this filing · 6 exited

LNGCheniere Energy Inc12.18%21,726,340$1.0Bheld—13 q
VSATViasat Inc9.96%13,158,137$840Mheld—16 q
unresolvedTwenty First Centy Fox Inc7.35%19,137,469$620Mheld—7 q
unresolvedColony Northstar Inc7.33%47,905,461$618Mnew+7.33 ppnew
SYFSynchrony Financial7.18%17,665,000$606Mtrimmed−15%−2.69 pp3 q
ACTAllergan PLC6.89%2,432,603$581Mtrimmed−29%−2.60 pp5 q
QRVOQorvo, Inc.5.84%7,185,514$493Mnew+5.84 ppnew
unresolvedDell Technologies Inc4.29%5,652,459$362Mtrimmed−15%−0.52 pp3 q
PBFPbf Energy Inc.4.13%15,724,175$349Mheld—15 q
TBPHTheravance Biopharma, Inc.4.05%9,273,991$341Mheld—12 q
ARAntero Resources Corporation3.92%14,505,881$331Mheld—11 q
QCOMQualcomm Inc3.55%5,216,000$299Mnew+3.55 ppnew
unresolvedTwenty First Centy Fox Inc2.74%7,278,100$231Mheld—7 q
INVAInnoviva, Inc.1.90%11,573,663$160Mtrimmed−22%−0.20 pp5 q
unresolvedKeryx Biopharmaceuticals Inc1.88%25,791,678$159Mheld—13 q
VRTVVeritiv Corporation1.87%3,044,385$158Mheld—11 q
MCKMcKesson Corporation1.76%1,000,000$148Mheld—2 q
unresolvedForward Pharma A/S1.42%5,575,407$120Madded+4%+0.36 pp10 q
ATRAGBXAtara Biotherapeutics Inc1.31%5,359,632$110Mheld—10 q
CAHCardinal Health, Inc.1.00%1,030,000$84Mheld—2 q
unresolvedExpress Scripts Hldg Co0.96%1,228,619$81Mnew+0.96 ppnew
unresolvedSilver Run Acquisition0.82%6,615,554$69Mnew+0.82 ppnew
unresolvedLiberty Ventures0.78%1,481,719$66Mheld—2 q
unresolvedChipmos Technologies Inc0.74%3,509,858$62Mheld—2 q
CACCCredit Acceptance Corp0.58%244,400$49Mheld—4 q
BATRKAtlanta Braves Holdings, Inc. Series C0.56%1,994,010$47Mtrimmed−33%−0.25 pp4 q
NGNovaGold Resources Inc.0.55%9,500,000$46Mheld—16 q
SYTSyngenta Ag-adr0.55%527,968$47Mtrimmed−29%−0.23 pp2 q
unresolvedGty Technology Holdings Inc0.54%4,400,000$45Mheld—2 q
CORCencora, Inc.0.53%502,474$44Mheld—2 q
CDEVPermian Resources Corporation0.49%2,407,153$42Mheld—2 q
unresolvedConyers Pk Acquisition0.47%3,712,500$39Mheld—3 q
PRTKParatek Pharmaceuticals, Inc.0.47%2,044,498$39Mheld—10 q
unresolvedCascadian Therapeutics Inc0.43%8,721,079$36Madded×2.1+0.19 pp2 q
unresolvedAmerican Intl Group Inc0.32%1,259,012$27Mtrimmed−51%−0.48 pp16 q
unresolvedSaban Cap Acquisition Corp0.28%2,326,500$23Mheld—2 q
RUNSunrun Inc0.18%2,848,082$15Mheld—7 q
unresolvedOrexigen Therapeutics Inc0.09%2,226,839$8Mheld—3 q
TMQTrilogy Metals Inc0.07%10,600,758$6Mheld—3 q
unresolvedConyers Pk Acquisition0.03%1,237,500$3Mheld—3 q
unresolvedSaban Cap Acquisition Corp0.02%1,163,250$2Mheld—2 q
unresolvedNorthstar Asset Mgmt Group I—−18,705,000—exited−3.67 pp—
unresolvedNorthstar Rlty Fin Corp—−14,577,134—exited−2.91 pp—
unresolvedColony Finl Inc—−6,959,017—exited−1.85 pp—
BATRAAtlanta Braves Holdings, Inc. Series A—−800,000—exited−0.22 pp—
LEXEALiberty Expedia Holdings, Inc. Class A—−395,613—exited−0.21 pp—
unresolvedCitigroup Inc—−62,903,207—exited−0.13 pp—

Other 13(f) securities

Options 0

None in this filing

Notes 2

Issue% of notesPrincipalValue
Theravance Biopharma Inc63.83%30,000,000$38M
Innoviva Inc36.17%22,480,000$21M

Source

Form
13F-HR/A
Reading
0 defects · 18 unresolved
Options
none in this filing
SEC cross-check
SEC data set not published yet